According to GlobalData's high-prescriber survey, approximately 40% of LA HNSCC patients receive definitive chemoradiotherapy ...

What is Keytruda and how does it work? Experts explain the cancer immunotherapy as a global investigation raises concerns ...

By Sabrina Valle NEW YORK, April 22 (Reuters) - Inhibrx Biosciences has drawn interest from drugmakers including Merck & Co, ...

Keytruda's first approval by US FDA came in the year 2014 for advanced skin cancer. Now, the immunotherapy drug is being used ...

First approved by the US FDA in 2014 for advanced skin cancer, Keytruda is now used globally for certain lung cancers, ...

Keytruda, an immunotherapy drug, is transforming cancer treatment in India by helping the immune system fight cancer cells.

A cross-border investigation by DW and ICIJ reveals how pricing and patents helped turn a life-saving medicine into one of ...

Merck & Co.'s Keytruda in the U.S. starts at $12,000 for a 200 mg dose. Costs go up from there based on the insurer, provider ...

Inhibrx Biosciences sparks interest from major drugmakers, including Merck, for its experimental cancer drug INBRX-106, potentially worth over $8 billion. The drug aims to boost the efficacy of ...

The Drug Controller General of India (DCGI) has approved Keytruda for multiple cancer types. As of recent approvals, it ...

By Sabrina Valle NEW YORK, April 22 (Reuters) - Inhibrx Biosciences has drawn interest from drugmakers including Merck & Co, ...